• The SSI Mantra surgical robotic system has surpassed the 100 surgery milestone

for robotic cardiac surgery

• SS Innovations maintains the world’s only comprehensive robotic cardiac surgery program
• SSI Mantra used in more than 1000 procedures globally

SS Innovations, the developer of India’s first indigenous surgical robotic system, the SSI Mantra, dedicated to making advance robotic surgeries cost-effective and accessible to a global population, today announced that 100 robotic cardiac surgery procedures have been successfully performed with the Company’s SSI Mantra Surgical Robotic System.

Dr. Sudhir Srivastava, SS Innovation’s Chairman and CEO, commented, “Reaching this milestone with the SSI Mantra is another notch in SS Innovations’ strategic market expansion—transforming practices, enhancing access, and driving the widespread use of robotic surgery. The Mantra’s innovative design, featuring a fifth arm capability, uniquely enables it to perform complex cardiac surgeries—a high demand market previously without an effective robotic solution.  Cardiac surgery often still requires a maximally invasive approach that involves splitting the patient’s sternum to gain access.”

“Our approach enables the same surgeries to be performed with minimal invasiveness, exemplifying the SSI Mantra system’s unique value proposition: precise execution, less trauma, reduced blood loss, quicker recoveries, and lower cost and superior overall outcomes. We anticipate receiving FDA and CE Mark approval in Europe in early 2025, further enhancing our market position,” Dr. Srivastava further said.

The global cardiac surgery device market was valued at $17.1 billion in 2023, according to ResearchAndMarkets. This is expected to increase over the forecast period at a CAGR of 5.5% to reach $24.9 billion. The global surgical robotics market size was valued at $78.8 billion in 2022, and is projected to reach $188.8 billion by 2032, growing at a CAGR of 9.1% from 2023 to 2032.

SS Innovations has established the world’s only comprehensive robotic cardiac surgery program, successfully executing procedures such as Totally Endoscopic Coronary Artery Bypass (TECAB), Internal Mammary Artery (IMA) Takedown, Mitral Valve Replacement, and Bilateral Internal Mammary Artery (BIMA) Takedown, all using the advanced SSI Mantra system.

Dr. Srivastava further emphasized, “We see a significant opportunity to address the global need for safe, timely, and affordable cardiac care. The successful use of the SSI Mantra in cardiac surgeries is transforming practices and setting the path to boost global adoption of robotic surgery. This progressoffers patients less invasive options and improved quality of life while positioning the Company to accelerate momentum and gain market share in valuable procedural territories.”

Dr. Nitin Kumar Rajput, Senior Consultant in Cardiac Surgery at Narayana Institute of Cardiac Sciences in Bangalore, India, individually performed about half of the surgeries, completing 47 robotic cardiac procedures.  He commented, “I have found that SS Innovations now has the most advanced system for coronary and intracardiac robotic cardiac surgeries, and we have performed bypass procedures, valve repairs and atrial septal defect closures. I believe that most robotic cardiac surgical procedures in the future will be done on the SSI Mantra Surgical Robotic System.”  

The successful completion of hundred cardiac surgeries marks a significant milestone for the SSI Mantra system, reaffirming its position as a game-changer in the field of healthcare technology. As SS Innovations continues to push the boundaries of innovation, the future holds immense promise for further advancements in surgical robotics, ultimately benefiting patients worldwide.